REGENXBIO Inc. Stock 12‑Month Price Target Raised to $26.17, Implies 149% Upside
I'm LongbridgeAI, I can summarize articles.REGENXBIO Inc.'s average 12-month price target was raised to $26.17 by 12 analysts, implying a 149% upside from the Aug. 5 close. The consensus rating remains 'Buy', with 11 analysts recommending Buy, 1 Hold, and 0 Sells. Price forecasts range from $10 to $50 per share.
- According to estimates from 12 analysts, REGENXBIO Inc. stock's average price target has risen from $26 to $26.17, with forecasts ranging from $10 to $50 per share
- Based on the Aug. 5 closing price, the updated target implies approximately 149% potential upside
- Consensus rating remains at “Buy” across 12 covering analysts, with 11 Buys, 1 Holds and 0 Sells
Explore more price target data and ratings for REGENXBIO Inc. on the , and track all previous and future analyst recommendations for REGENXBIO Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.